← All Stories
Deal Flow

Windward Bio lists on Nasdaq after pricing IPO at $17 per share

Windward Bio (Nasdaq: WWB) listed on Nov. 13, 2026, pricing its IPO at $17 and closing at $28.50 on its first trading day.

Stock market analysis setup with charts, phone, magnifier, and clipboards.
Photo by Leeloo The First on Pexels

Windward Bio, a clinical-stage biotechnology company and a portfolio company of Qiming Venture Partners, listed on Nasdaq on November 13, 2026, after pricing its IPO at $17.00 per share, according to PR Newswire. Windward Bio trades under the ticker WWB, and its shares closed at $28.50 on the first trading day, which PR Newswire reported as up 68% from the IPO price and implying a market capitalization of approximately $1.69 billion.

Qiming Venture Partners’ involvement across Series A, Series B, and the IPO

Qiming Venture Partners invested in Windward Bio’s inaugural Series A financing in 2025 and continued to support the company in its Series B financing in 2026, according to PR Newswire. Qiming also participated in the IPO financing round.

PR Newswire described Windward Bio as Qiming Venture Partners’ 11th IPO in 2026.

Qiming Venture Partners was founded in 2006 and currently manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised, according to PR Newswire. PR Newswire said Qiming has backed over 630 companies and reported that over 290 of its portfolio companies have achieved exits through IPOs on the NYSE, NASDAQ, HKEX, the Shanghai Stock Exchange, or the Shenzhen Stock Exchange, or through M&A or other means.

Company focus and therapeutic areas

Windward Bio was founded in 2024 with a mission to transform the treatment paradigm for patients living with chronic inflammatory diseases through the development of differentiated biologic therapies targeting clinically validated disease pathways, according to PR Newswire. PR Newswire said the company is led by a team with expertise across discovery, development, and commercialization.

PR Newswire reported that Windward Bio is advancing a pipeline of ultra-long-acting antibody medicines intended to improve clinical outcomes, reduce treatment burden, and expand treatment options for patients with serious respiratory and dermatologic diseases, including asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis.

Lead programs and licensing arrangements

Windward Bio’s lead program is WIN378, which PR Newswire described as a potentially novel anti-TSLP monoclonal antibody engineered for improved potency and extended half-life. PR Newswire reported that WIN378 is being evaluated in POLARIS-1, a Phase 2/3 study in severe uncontrolled asthma, and in SIRIUS, a Phase 2 study in COPD.

PR Newswire said the company’s pipeline also includes WIN027, a clinical-stage, long-acting bispecific antibody targeting TSLP and IL-13 with potential applications across multiple inflammatory and immunological diseases.

Windward Bio holds exclusive global rights, excluding Greater China and certain Asian countries, to WIN378 through a licensing agreement with Kelun-Biotech and Harbour BioMed, according to PR Newswire. PR Newswire also reported that Windward Bio separately licensed WIN027 from Qyuns Therapeutics.

Widely known context: Nasdaq is a U.S. stock exchange where companies list shares for public trading, and IPO stands for initial public offering.

Sources
Topics
  • #Windward Bio
  • #Qiming Venture Partners
  • #Nasdaq
  • #biotechnology
  • #IPO
Get capital raising signals before they hit the news.
Join Waitlist